Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IBIO Stock Forecast 2025-2026
$0.90
Current Price
$13.46M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to IBIO Price Targets
+566.7%
To High Target of $6.00
+455.6%
To Median Target of $5.00
+300.0%
To Low Target of $3.60
IBIO Price Momentum
-12.6%
1 Week Change
+12.5%
1 Month Change
-60.5%
1 Year Change
-63.3%
Year-to-Date Change
-86.9%
From 52W High of $6.89
+40.6%
From 52W Low of $0.64
📊 TOP ANALYST CALLS
Did IBIO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if iBio is one of their latest high-conviction picks.
Latest IBIO Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, IBIO has a bullish consensus with a median price target of $5.00 (ranging from $3.60 to $6.00). Currently trading at $0.90, the median forecast implies a 455.6% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Dev Prasad at LUCID CAPITAL MARKETS, projecting a 566.7% upside. Conversely, the most conservative target is provided by Kemp Dolliver at Brookline Capital, suggesting a 300.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IBIO Analyst Ratings
3
Buy
0
Hold
0
Sell
IBIO Price Target Range
Low
$3.60
Average
$5.00
High
$6.00
Current: $0.90
Latest IBIO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IBIO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 6, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $5.00 |
| May 5, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $5.00 |
| Dec 17, 2024 | LUCID CAPITAL MARKETS | Dev Prasad | Buy | Initiates | $6.00 |
| Jul 22, 2024 | Brookline Capital | Kemp Dolliver | Buy | Initiates | $3.60 |
| Jun 3, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $5.00 |
| May 28, 2024 | Chardan Capital | Keay Nakae | Buy | Initiates | $5.00 |
| Feb 16, 2023 | JMP Securities | Roy Buchanan | Market Perform | Downgrade | $0.00 |
| Oct 7, 2022 | Cantor Fitzgerald | Kristen Kluska | Neutral | Downgrade | $0.17 |
| Nov 29, 2021 | JMP Securities | Roy Buchanan | Outperform | Initiates | $1.50 |
| Jan 22, 2021 | Cantor Fitzgerald | Overweight | Initiates | $0.00 | |
| Jan 21, 2021 | Cantor Fitzgerald | Overweight | Initiates | $0.00 | |
| Jun 26, 2020 | Alliance Global Partners | Buy | Initiates | $0.00 |
iBio, Inc. (IBIO) Competitors
The following stocks are similar to iBio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
iBio, Inc. (IBIO) Financial Data
iBio, Inc. has a market capitalization of $13.46M with a P/E ratio of 0.6x. The company generates $375,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -100.0% quarter-over-quarter, while maintaining an operating margin of -4,483.5% and return on equity of -90.8%.
Valuation Metrics
Market Cap
$13.46M
Enterprise Value
$12.82M
P/E Ratio
0.6x
PEG Ratio
-0.5x
Price/Sales
35.9x
Growth & Margins
Revenue Growth (YoY)
-100.0%
Gross Margin
N/A
Operating Margin
-4,483.5%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+33.3%
Current Ratio
1.1x
Debt/Equity
38.0x
ROE
-90.8%
ROA
-30.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
iBio, Inc. (IBIO) Business Model
About iBio, Inc.
What They Do
Develops plant-based biopharmaceuticals.
Business Model
iBio operates a business model centered on the development and commercialization of biopharmaceuticals using its proprietary FastPharming technology. This platform enables the efficient production of recombinant proteins necessary for vaccines, therapeutics, and diagnostics, allowing the company to generate revenue through partnerships and sales in the healthcare sector.
Additional Information
iBio's focus on sustainability and cost reduction in drug manufacturing makes it a significant player in addressing urgent healthcare needs, such as infectious diseases and cancer. Their innovative approach could position them well in a market that demands rapid responses and affordability.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
16
CEO
Dr. Martin B. Brenner D.V.M., Ph.D.
Country
United States
IPO Year
2008
Website
ibioinc.comiBio, Inc. (IBIO) Latest News & Analysis
Latest News
Quick Summary
iBio, Inc. has nominated IBIO-610, a first-in-class Activin E antibody, for development. A study on its efficacy in non-human primates will assess fat reduction and body composition.
Why It Matters
iBio's nomination of IBIO-610 highlights potential breakthroughs in obesity treatment, signaling growth opportunities and innovation, which can influence stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
iBio, Inc. (Nasdaq: IBIO) announced promising preclinical results for its Activin E antibody, showing a 26% fat mass reduction in obese mice while preserving muscle mass.
Why It Matters
Positive preclinical data for iBio's Activin E antibody suggests potential market differentiation in obesity treatments, which could enhance stock value and investor confidence in future profitability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
iBio, Inc. (Nasdaq: IBIO) announced its financial results for Q3 ending March 31, 2025, and provided a corporate update.
Why It Matters
iBio's financial results and corporate updates can influence stock performance, investor sentiment, and market expectations, impacting investment decisions regarding the company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
iBio, Inc. has secured an agreement with institutional investors to exercise existing warrants for 5.63 million shares at $1.11 each, raising approximately $6.2 million for working capital.
Why It Matters
iBio's agreement to exercise existing warrants at a reduced price raises $6.2 million, enhancing liquidity for operations, which may positively impact share value and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
iBio has licensed a novel activin E antibody, highlighting its focus on developing treatments for obesity and cardiometabolic diseases.
Why It Matters
iBio's in-licensing of a novel antibody signals potential for new revenue streams and growth in the obesity and cardiometabolic market, enhancing its competitive position.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
IBIO-600, a long-acting anti-myostatin antibody, may have a human half-life of up to 130 days based on non-human primate pharmacokinetics data.
Why It Matters
IBIO-600's long potential human half-life indicates significant efficacy and market potential, enhancing investor interest in its commercial viability and competitive positioning.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About IBIO Stock
What is iBio, Inc.'s (IBIO) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, iBio, Inc. (IBIO) has a median price target of $5.00. The highest price target is $6.00 and the lowest is $3.60.
Is IBIO stock a good investment in 2025?
According to current analyst ratings, IBIO has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.90. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IBIO stock?
Wall Street analysts predict IBIO stock could reach $5.00 in the next 12 months. This represents a 455.6% increase from the current price of $0.90. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is iBio, Inc.'s business model?
iBio operates a business model centered on the development and commercialization of biopharmaceuticals using its proprietary FastPharming technology. This platform enables the efficient production of recombinant proteins necessary for vaccines, therapeutics, and diagnostics, allowing the company to generate revenue through partnerships and sales in the healthcare sector.
What is the highest forecasted price for IBIO iBio, Inc.?
The highest price target for IBIO is $6.00 from Dev Prasad at LUCID CAPITAL MARKETS, which represents a 566.7% increase from the current price of $0.90.
What is the lowest forecasted price for IBIO iBio, Inc.?
The lowest price target for IBIO is $3.60 from Kemp Dolliver at Brookline Capital, which represents a 300.0% increase from the current price of $0.90.
What is the overall IBIO consensus from analysts for iBio, Inc.?
The overall analyst consensus for IBIO is bullish. Out of 6 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $5.00.
How accurate are IBIO stock price projections?
Stock price projections, including those for iBio, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 5:19 AM UTC